A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Recruiting now · Phase 2

Conditions studied: Malignant Neoplasm

In brief

Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.

Key facts

Study ID: NCT06979596
Run by: Merck Sharp & Dohme LLC
People needed: 250
Starts: 2025-08-11
Expected to finish: 2027-11-04
Last updated by the study team: 2026-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

The main inclusion criteria include but are not limited to the following:
Cohort A:
Has a diagnosis of hormone receptor positive/Human Epidermal Growth Factor Receptor 2 negative (HR+/HER2-) invasive breast carcinoma that is either locally advanced disease not amenable to resection with curative intent (herein called unresectable) or metastatic disease not treatable with curative intent.
Has experienced disease progression on or after at least 1 prior endocrine-based therapy in the metastatic setting and received either, 1 line of an approved protocol-specified combination endocrine-based therapy, or 2 or more lines of protocol-specified endocrine-based therapy in the metastatic setting
Cohort B:
Has histologically confirmed high-grade epithelial (including high-grade serous or predominantly serous, high-grade endometrioid, malignant mixed Müllerian tumors [carcinosarcoma], or clear cell) ovarian, fallopian tube, or primary peritoneal carcinoma.
Has received between 4 to 8 cycles of platinum-based doublet chemotherapy in third-line (3L) setting for ovarian cancer.
Cohort C:
Histologically confirmed diagnosis of primary advanced or recurrent low-grade endometrioid carcinoma (eg, Federation of Gynecology and Obstetrics [FIGO] Grade 1/2, or well/moderately differentiated).
Treatment naïve or has received up to 1 prior line of platinum-based therapy in either the advanced/metastatic OR adjuvant/neoadjuvant setting.
All Cohorts :
Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline.
Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
Participants who are Hepatitis B surface antigen positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.
Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.

You may not qualify if…

The main exclusion criteria include but are not limited to the following:
Cohort A:
Breast cancer amenable to treatment with curative intent.
Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications, such as lymphangitic lung metastases, radiographic evidence of intratumoral cavitation or invasion/infiltration of a major blood vessel, bone marrow replacement, carcinomatous meningitis, significant symptomatic liver metastases, symptomatic pericardial effusion, symptomatic peritoneal carcinomatosis, or the need to achieve rapid symptom control.
Cohort B:
Has nonepithelial cancers (germ cell tumors and sex cord-stromal tumors), borderline tumors (low malignant potential), mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor, low-grade serous, low-grade endometrioid, and undifferentiated carcinoma.
Has platinum-resistant ovarian cancer (defined as disease that has progressed per radiographic imaging within 180 days after the last dose of first-line [1L] platinum-based therapy) or platinum-refractory ovarian cancer (defined as disease that has progressed per radiographic imaging while receiving or within 28 days of the last dose of 1L platinum based therapy).
Is a candidate for curative-intent surgery or curative-intent radiotherapy for ovarian cancer.
Cohort C:
Has high-grade (FIGO Grade 3 or poorly differentiated) endometrioid carcinoma and nonendometrioid histologies of any type (including serous, clear cell, mixed, carcinosarcoma), and neuroendocrine tumors are not eligible. Uterine mesenchymal tumors such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas, and adenosarcomas are not eligible.
Is a candidate for curative-intent surgery or curative-intent radiotherapy.
All Cohorts:
Has confirmed or suspected adrenal metastases.
Has known difficulty in tolerating oral medications, unable to swallow orally administered medication, or conditions which would impair absorption of oral medications.
Has any prior history or current condition of adrenal insufficiency.
HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
Has known active central nervous system metastases and/or carcinomatous meningitis.
Has a history of stem cell/solid organ transplant.
Has not adequately recovered from major surgery or has ongoing surgical complications.

Where it is running

Mount Sinai Cancer Center ( Site 0009) — Miami Beach, Florida, United States (enrolling)
TRIALS 365 ( Site 0022) — Shreveport, Louisiana, United States (enrolling)
Mary Lanning Healthcare ( Site 0019) — Hastings, Nebraska, United States (enrolling)
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0021) — Hackensack, New Jersey, United States (enrolling)
Rockefeller Outpatient Pavilion ( Site 0002) — New York, New York, United States (enrolling)
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0008) — Columbus, Ohio, United States (enrolling)
Baylor College of Medicine Medical Center ( Site 0004) — Houston, Texas, United States (enrolling)
Harris Health System ( Site 0040) — Houston, Texas, United States (enrolling)
Mays Cancer Center ( Site 0039) — San Antonio, Texas, United States (enrolling)
Hospital Aleman ( Site 0301) — Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina (enrolling)
Centro Medico Dr. Doreski - Fundación Respirar ( Site 0302) — Buenos Aires, Buenos Aires F.D., Argentina (enrolling)
Instituto Alexander Fleming ( Site 0303) — Buenos Aires, Buenos Aires F.D., Argentina (enrolling)
Hospital Santa Rita de Cassia ( Site 3104) — Vitória, Espírito Santo, Brazil (enrolling)
Obras Sociais Irma Dulce ( Site 3112) — Salvador, Estado de Bahia, Brazil (enrolling)
Hospital Felicio Rocho ( Site 3105) — Belo Horizonte, Minas Gerais, Brazil (enrolling)
Hospital de Cancer de Pernambuco ( Site 3103) — Recife, Pernambuco, Brazil (enrolling)
Liga Norte Riograndense Contra o Cancer ( Site 3108) — Natal, Rio Grande do Norte, Brazil (enrolling)
Instituto Nacional de Câncer - INCA ( Site 3107) — Rio de Janeiro, Brazil (enrolling)
Princess Margaret Cancer Centre ( Site 0202) — Toronto, Ontario, Canada (enrolling)
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0200) — Montreal, Quebec, Canada (enrolling)
Jewish General Hospital ( Site 0201) — Montreal, Quebec, Canada (enrolling)
FALP ( Site 3300) — Santiago, Region M. de Santiago, Chile (enrolling)
Pontificia Universidad Catolica de Chile ( Site 3307) — Santiago, Region M. de Santiago, Chile (enrolling)
Bradfordhill ( Site 3301) — Santiago, Region M. de Santiago, Chile (enrolling)
Alaska Womens Cancer Care ( Site 0037) — Anchorage, Alaska, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.